Cefotaxime
- Generic Name
- Cefotaxime
- Brand Names
- Claforan
- Drug Type
- Small Molecule
- Chemical Formula
- C16H17N5O7S2
- CAS Number
- 63527-52-6
- Unique Ingredient Identifier
- N2GI8B1GK7
- Background
Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis).
- Indication
Used to treat gonorrhoea, meningitis, and severe infections including infections of the kidney (pyelonephritis) and urinary system. Also used before an operation to prevent infection after surgery.
- Associated Conditions
- Bone and Joint Infections caused by susceptible Bacterial Infections, Central Nervous System Infections caused by susceptible Bacterial Infections, Genitourinary tract infection caused by susceptible Bacterial Infections, Gynaecological infection caused by susceptible bacteria, Intraabdominal Infections caused by susceptible Bacterial Infections, Lower Respiratory Tract Infection (LRTI) caused by susceptible bacteria, Postoperative Wound Infection, Septicemia caused by susceptible Bacterial Infections, Skin and skin-structure infections caused by susceptible bacteria
Aminoglycosides in Early Sepsis
- Conditions
- Sepsis
- Interventions
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- University Hospital, Akershus
- Target Recruit Count
- 1940
- Registration Number
- NCT06712641
- Locations
- 🇳🇴
Akershus University Hospital, Lørenskog, Norway
🇳🇴Oslo University Hospital Ullevål, Oslo, Norway
LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Media
- Conditions
- Upper Respiratory Tract Infections
- Interventions
- Drug: 0.9% NaCl physiological saline Nasal-sprayingCombination Product: LiveSpo Navax®
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Anabio R&D
- Target Recruit Count
- 175
- Registration Number
- NCT05804123
- Locations
- 🇻🇳
Thai Binh University of Medicine and Pharmacy, Thai Binh Medical University Hospital and Thai Binh Children's Hospital, Thai Binh, Vietnam
Meropenem vs Cefotaxime as Empirical Treatment of SBP
- First Posted Date
- 2022-06-22
- Last Posted Date
- 2022-06-22
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 286
- Registration Number
- NCT05427747
Oral Gemifloxacin Versus Intravenous Cefotaxime in Treatment of Spontaneous Bacterial Peritonitis
- Conditions
- Spontaneous Bacterial Peritonitis
- Interventions
- First Posted Date
- 2019-11-19
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 60
- Registration Number
- NCT04168099
- Locations
- 🇪🇬
Sherief Abd-Elsalam, Tanta, Egypt
Effect of Administration of 3rd Generation Cephalosporin on the Digestive Carrying of 3rd Generation Cephalosporin-resistant Enterobacteriaceae (CEF-IMPACT)
- Conditions
- Infectious Disease - Resistant Enterobacteriaceae (Diagnosis)
- Interventions
- First Posted Date
- 2019-04-22
- Last Posted Date
- 2019-04-22
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 250
- Registration Number
- NCT03922919
- Locations
- 🇫🇷
CHU de Besançon, Besançon, France
Disturbance of the Intestinal Microbiota by Temocillin vs Cefotaxime in Treatment of Febrile Urinary Tract Infections
- First Posted Date
- 2016-11-09
- Last Posted Date
- 2019-09-16
- Lead Sponsor
- Håkan Hanberger
- Target Recruit Count
- 157
- Registration Number
- NCT02959957
- Locations
- 🇸🇪
Centralsjukhuset Kristianstad, Kristianstad, Sweden
🇸🇪Västmanlands sjukhus i Västerås, Västerås, Sweden
🇸🇪Karolinska University Hospital, Solna, Stockholm, Sweden
Impact of the Choice of 3rd Generation Cephalosporins on the Emergence of Resistance in the Microbiota Intestinal.
- Conditions
- Emergence of Bacterial Resistance to Antibiotics
- Interventions
- First Posted Date
- 2016-01-20
- Last Posted Date
- 2018-05-21
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 22
- Registration Number
- NCT02659033
- Locations
- 🇫🇷
Hôpital Bichat, Paris, France
Randomized Trial of Continuous Versus Intermittent Cefotaxime Infusion on ICU.
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 60
- Registration Number
- NCT02560207
- Locations
- 🇳🇱
University Medical Center Groningen, Groningen, Netherlands
Is Spontaneous Bacterial Peritonitis Still Responding to 3rd Generation Cephalosporins?
- First Posted Date
- 2015-05-13
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 100
- Registration Number
- NCT02443285
- Locations
- 🇪🇬
Tanta university - faculty of medicine, Cairo, Egypt
Cefotaxime Resistance in Treatment of Spontaneous Bacterial Peritonitis
- First Posted Date
- 2015-03-13
- Last Posted Date
- 2015-06-04
- Lead Sponsor
- Dr Ahmed Ali Elbaz
- Target Recruit Count
- 254
- Registration Number
- NCT02388035
- Locations
- 🇪🇬
Nasser institute, Cairo, Shubra, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.